文献速递糖尿病

聚类与否?TriMaster交叉试验中2型糖尿病降糖治疗精准策略的比较

To Cluster or Not to Cluster? A Comparison of Approaches to Targeting Type 2 Diabetes Glucose-Lowering Therapy in the TriMaster Crossover Trial.
PubMed 文献 · Diabetes Care · 2026-01-01

本研究在309例接受西格列汀、卡格列净和吡格列酮三种药物治疗的2型糖尿病患者中,比较了四种精准治疗策略预测4个月HbA1c总体反应和个体内差异反应的能力。结果显示,常规特征模型和聚类方法与总体及差异HbA1c反应均强相关,但常规特征模型在优化短期HbA1c降低方面优于聚类分配。

要点

  • 常规特征模型比聚类方法更能优化短期HbA1c降低。
  • 临床特征与血糖差异反应的关联强于多基因风险评分。
  • 直接结局预测优于数据驱动的亚组分类。

核心结论

  • 在2型糖尿病降糖治疗选择中,直接结局预测模型在优化短期HbA1c降低方面优于基于聚类的分配策略。

研究设计与样本

  • TriMaster三向交叉试验,纳入309例接受西格列汀、卡格列净和吡格列酮三种药物治疗的2型糖尿病成人。
  • 评估四种精准治疗策略预测4个月HbA1c总体反应和个体内差异反应的能力。

主要发现

  • 常规特征模型和聚类方法均与总体及差异HbA1c反应强相关(P < 0.0001)。
  • 常规特征模型在所有药物比较中均识别出最有效治疗,而临床聚类仅在一个聚类-药物比较中显示获益(严重胰岛素抵抗型糖尿病:SGLT2i vs. TZD,P = 0.005)。
  • DDRTree分析与治疗反应无关;8个PPS中仅2个与差异反应有适度关联(脂肪代谢障碍PPS对SGLT2 vs. TZD反应更大;β细胞功能障碍、负性胰岛素原PPS对TZD vs. DPP4i反应更大)。
  • 基于常规特征模型的治疗分配比基于聚类的分配带来更大的HbA1c降低(0.27% [95% CI 0.18, 0.35],2.9 mmol/mol [95% CI 2.0, 3.8] vs. 0.16% [95% CI 0.07, 0.25],1.7 mmol/mol [95% CI 0.8, 2.7])。

临床怎么用

  • 临床实践中,可优先考虑基于常规临床特征直接预测治疗反应的模型来选择降糖药物,而非依赖数据驱动的聚类分组。

局限性

  • 研究仅评估了短期(4个月)HbA1c反应,长期结局未知。
  • 样本量有限(309例),结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Different precision treatment approaches have been proposed for type 2 diabetes, but robust comparisons are lacking. We compared the utility of proposed approaches targeting glucose-lowering therapy in the TriMaster three-way crossover trial. RESEARCH DESIGN AND METHODS: We evaluated four previously reported precision treatment strategies for their ability to predict overall 4-month HbA1c response and within-person differential response to sitagliptin, canagliflozin, and pioglitazone in 309 adults with type 2 diabetes who received all three medications. Approaches included allocation to clusters based on routine features and HOMA, direct outcome prediction using a routine-features treatment-selection model, type 2 diabetes cluster-specific partitioned polygenic scores (PPSs), and a model based on discriminative dimensionality reduction tree (DDRTree) analysis. RESULTS: The routine-features model and cluster approach were both strongly associated with overall and differential HbA1c responses (P < 0.0001). The routine-features model identified the most effective therapy with significant benefit across all drug comparisons, whereas clinical clusters showed benefit for only one cluster-drug comparison (severe insulin-resistant diabetes: SGLT2i vs. thiazolidinedione [TZD], P = 0.005). DDRTree was not associated with treatment response. Of eight PPSs, only two showed modest association with differential response (lipodystrophy PPS had a greater response to SGLT2 vs. TZD; and β-cell dysfunction, negative proinsulin PPS had a greater response to TZD vs. dipeptidyl peptidase 4 inhibitor). Treatment allocation based on the routine-features model resulted in greater HbA1c reduction than cluster-based allocation (0.27% [95% CI 0.18, 0.35], 2.9 mmol/mol [95% CI 2.0, 3.8] vs. 0.16% [95% CI 0.07, 0.25], 1.7 mmol/mol [95% CI 0.8, 2.7]). CONCLUSIONS: Clinical features are more strongly associated with differential glycemic response than PPS, and direct outcome prediction outperforms data-driven subgrouping for optimizing short-term HbA1c reduction.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Güdemann LM, Angwin C, Holman RR, et al. To Cluster or Not to Cluster? A Comparison of Approaches to Targeting Type 2 Diabetes Glucose-Lowering Therapy in the TriMaster Crossover Trial. Diabetes Care. 2026. PMID: 42312889. doi:10.2337/dc26-0118

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。